EUCTR2014-003197-16-IT进行中（未招募）1 期
A Phase III randomized, controlled, open-label on the effects of parenteral nutrition early start to the late start in the ICU cardiac surgery
Bambino Gesù Children's Hospital0 个研究点开始时间: 2014年8月28日最近更新:
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •- Age 0-18 years, of both sexes;
- •- Parents or guardians are able to give their written informed consent and comply with study procedures;
- •- Patients waiting for surgery or palliative / corrective pediatric cardiac surgery;
- •- Patients requiring parenteral nutrition via central and peripheral, lasting a minimum of 7 days
- •- Written informed consent of the parents or legal guardians of patients
- •Are the trial subjects under 18? yes
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- •- Patients with associated malformations
- •- Patients with coagulopathies
研究者
相似试验
进行中（未招募）
1 期
To evaluate the efficacy of albumin administration in patients hospitalized with community-acquired pneumonia (ALBUCAP)EUCTR2018-003117-18-ESDr. Jordi Carratalà Fernández (Servicio de Enfermedades Infecciosas) del Hospital Universitario de Bellvitge360
进行中（未招募）
3 期
A Phase III Randomized, Controlled, Open-label, Multicenter, Global Study of Capmatinib in Combination With Osimertinib Versus Platinum - Pemetrexed Based Doublet Chemotherapy in Patients With Locally Advanced or Metastatic NSCLC Harboring EGFR Activating Mutations Who Have Progressed on Prior 1st / 2nd Generation EGFR-TKI or Osimertinib Therapy and Whose Tumors Are T790M Mutation Negative and Harbor MET Amplification (GEOMETRY-E)Carcinoma, Non-Small-Cell LungJPRN-jRCT2041210072Suzuki Kazuyuki245
进行中（未招募）
1 期
Study of safety and efficacy of capmatinib in combination with osimertinib compared to platinum - pemetrexed based doublet chemotherapy in patients with locally advanced or metastatic non-small cell lung cancer harboring EGFR activating mutations and T790M negative who have progressed on prior EGFR-TKI therapyEGFR mutated, T790M negative NSCLCMedDRA version: 21.1Level: PTClassification code 10061873Term: Non-small cell lung cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2020-003677-21-BGovartis Pharma AG6
进行中（未招募）
1 期
Study of safety and efficacy of capmatinib in combination with osimertinib compared to platinum - pemetrexed based doublet chemotherapy in patients with locally advanced or metastatic non-small cell lung cancer harboring EGFR activating mutations and T790M negative who have progressed on prior EGFR-TKI therapyEUCTR2020-003677-21-HUovartis Pharma AG245
进行中（未招募）
1 期
Study of safety and efficacy of capmatinib in combination with osimertinib compared to platinum - pemetrexed based doublet chemotherapy in patients with locally advanced or metastatic non-small cell lung cancer harboring EGFR activating mutations and T790M negative who have progressed on prior EGFR-TKI therapyEGFR mutated, T790M negative NSCLCMedDRA version: 21.1Level: PTClassification code 10061873Term: Non-small cell lung cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2020-003677-21-DEovartis Pharma AG245